Zealand Pharma A/S (ZLDPF)
ValueMarkers Composite Index
DCF data not available
Zealand Pharma A/S (ZLDPF) — VMCI valuation read
ZLDPF prints VMCI 74/100 inside the Healthcare sector, where the median sits at 50. The 24-point above-median delta is the cleanest single-number summary of Zealand Pharma A/S's composite stance, and in the mid-cap bucket it places the share ahead of the typical peer on the five-pillar mix.
On ZLDPF, the SEC EDGAR Form 4 stream shows no insider buys or sells in the past 30 days. Quiet tapes happen; they just remove a signal that bull and bear cases sometimes lean on for confirmation.
**Investor frame.** ZLDPF trades at 18.0x earnings, 0% above the Healthcare median of 18.0x; that is the value line. ROIC of 18.0% sits 8.0pp above the Healthcare median (10.0%); that is the quality line. net debt to EBITDA of 3.4x is the binding constraint on the bear case; that is the risk line for Zealand Pharma A/S on the trailing financials.
ZLDPF fell 1.7% over the trailing 7 days, with a +5.6% read on a 30-day basis.
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company markets lixisenatide under the brand names of Adlyxin and Lyxumia; Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia, congenital hyperinsulinism, and post bariatric surgery hypoglycemia; and Dasiglucagon dual-hormone artificial pancreas for automated diabetes management. The company's pipeline includes Dasiglucagon that is in Phase III clinical trials for congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S has collaboration agreements with Sanofi-Aventis Deutschland GmbH; Boehringer Ingelheim International GmbH; Alexion Pharmaceuticals, Inc.; and Beta Bionics, Inc. The company was incorporated in 1998 and is headquartered in Copenhagen, Denmark.
Related Stocks in Healthcare
Top peers ranked by VM Score. Compare valuation, quality, and risk metrics across the sector.